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The experience of UK patients with bladder cancer
during the COVID-19 pandemic: a survey-based
snapshot
The COVID-19 pandemic has placed unprecedented strain on
healthcare systems worldwide with the requirement to treat
large influxes of infected patients, many of whom require
respiratory support. Healthcare systems have had to redirect
resources and redeploy staff away from routine diagnostic,
treatment and follow-up services. The NHS in the UK is no
different, and cancer services have undergone significant
disruption to create the emergency capacity to tackle the
pandemic. As a charity that endeavours to support bladder
cancer (BC) patients and improve outcomes, Action Bladder
Cancer UK (ABC UK, Tetbury, UK) designed and
administered an online survey to investigate the prevalence of
such disruption.
Using the SurveyMonkey platform (San Mateo, CA, USA),
the survey was launched on 22 April 2020 (approximately
10 days after the peak of UK COVID-19 cases) and closed on
22 July 2020. BC patients were directed to the survey via the
ABC UK website (http://actionbladdercanceruk.org/), ABC
UK Patient Support Groups, and social media platforms. In
addition to the collection of anonymized demographic and
tumour-specific characteristics, the first three digits of each
postcode were converted into area type using Office for
National Statistics postcode data and categorized as rural,
urban city and town, and urban major conurbation.
Associations between area type and disruption were assessed
using the chi-squared test. The analysis of these data was
approved by the King’s College London Research Ethics
Office.
In the time from inception to completion, 156 patients with
BC responded. Over 94% of respondents lived in England,
although there was geographical reach from all of the UK. A
total of 34% of patients were from rural areas, 29% were
from urban cities and towns, and 22% were from major
conurbations such as West Yorkshire, Greater Manchester
and Greater London (15% did not submit postcodes). Almost
80% of respondents were aged 60 years or older and more
than 68% were men. Approximately 71% of respondents had
non-muscle-invasive BC (NMIBC), 22% had muscle-invasive
BC (MIBC), and 3% had a diagnosis of advanced/metastatic
disease.
Across all groups, 49% of patients described disruption to
their treatment or follow-up (delays, postponements, or
cancellations/curtailments), while 33% of patients indicated
no change, with treatment and follow-up proceeding as
normal. The majority of the remaining 18% of patients were
scheduled for follow-up several months in the future and had
not yet been informed of any changes. There was no
association between area type (rural/urban) and disruption to
treatment. This lack of association remained when stratified
by NMIBC vs MIBC/advanced disease.
In patients who described disruption, 50% had received a
telephone call to inform them, 27% had received a letter, 2%
had received a text message, and 21% had contacted the
hospital themselves; 33% reported that the pandemic had
made it more difficult to communicate with their urology
team.
Eight respondents were awaiting their initial transurethral
resection of bladder tumour (TURBT); for two of these
patients, TURBT had been delayed or postponed (Table 1).
Sixteen patients were awaiting a subsequent TURBT (for re-
resection or recurrence); for six of these patients, TURBT had
been delayed or postponed. Ninety-seven patients described
being under cystoscopic surveillance, 85% of whom had
NMIBC and 14% MIBC (one patient did not specify their
disease status). A total of 51 patients (53%) reported a delay
or postponement to their surveillance (Table 1). Of 53
patients with NMIBC undergoing courses of intravesical
therapy, 37 (70%) described delays, postponements or
curtailments in treatment (Table 1).
Seventeen patients were awaiting cystectomy, of whom nine
had been notified of a postponement in their surgery, and
three had been notified of cancellation of their surgery
(Table 1). Two patients’ treatment plans changed from
cystectomy to radiotherapy; there were no patients who
changed from radiotherapy to cystectomy, and no patients
described disruption to radiotherapy or neoadjuvant
chemotherapy (Table 1).
Eight patients described undergoing treatment regimens for
locally advanced or metastatic disease (adjuvant
chemotherapy or chemotherapy only); five of these patients
described disruption to the administration of chemotherapy
(Table 1).
Regarding COVID-19 itself, 67 respondents (43%) had been
advised to shield, and the majority of the remainder felt that
they should have been advised to shield and shielded anyway.
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A total of 76% of patients expressed some concern about
attending hospital for their treatment and follow-up
appointments, and approximately 64% described that safety
precautions for themselves and for staff would make them
feel safer when attending.
The outputs of this survey have demonstrated the
considerable disruption to the care of BC patients in the UK
during the COVID-19 pandemic. Notably, the level of
disruption was not significantly different between patients
from different types of geographical area (e.g. rural or urban),
with the survey capturing a representative sample of the BC
population: the majority of respondents were both male and
aged >60 years, and approximately 71% were NMIBC
patients.
It was also interesting to observe that, although fewer than
half of the patients were advised to shield, the majority of
patients did so anyway. This response is reflected in the high
levels of concern and/or anxiety reported by patients
regarding returning to hospital to continue treatment and/or
follow-up.
A survey of this nature has a number of limitations. Although
the patient demographics accurately reflect those of the UK
BC population, this remains a relatively small study using an
unvalidated questionnaire. The survey was more likely to be
completed by existing patients with BC who are already
engaged with ABC UK, rather than newly diagnosed patients
who may not yet be aware of the charity’s work.
Furthermore, local or regional patterns have not been
captured comprehensively, and more nuanced responses to
the survey may have been obtained via telephone interview.
Patients with BC in the UK are not alone in experiencing
disruption to their care during the pandemic [1,2]. Some of
these disruptions will have been justified in order to protect
patients from COVID-19 itself or from additional
complications of specific treatments in the environment of the
pandemic [2–4]; yet much disruption will have directly
resulted from the emergency redeployment of healthcare
services to tackle the pandemic. Our survey appears to
demonstrate that both MIBC and NMIBC patients have been
equally affected by delays, postponements and cancellations
during the COVID-19 pandemic. Hence, despite a plethora of
recommendations from a number of sources outlining
reasonable patient prioritization strategies [2,5–7], these
strategies may not have been developed and circulated quickly
enough or enacted rapidly enough at or around the peak of
the UK pandemic to have made a perceivable difference to
patients. Given the overwhelming nature of the pandemic on
the whole of society, this is understandable. However, it is
critical that the BC clinical and academic community
maintains an ‘institutional memory’ should similar
circumstances ensue in the form of a second wave of COVID-
19, or as a separate threat. Now is the time to plan effective
contingent ways of working and agree upon protocols that
minimize the disruption to high-quality bladder cancer care
should either scenario become reality; considerable evidence is
available to inform such strategies [5,6], including publications







Notwithstanding, the true success of any strategy in the
cancer setting can only be appropriately assessed several years
downstream in terms of clinical outcomes; potential health-
related quality-of-life deficits should not be forgotten, and we
are planning follow-up surveys to attempt to capture the
physical and psychological burden of the treatment
disruptions and postponements. Furthermore, we should be
aware that new suspected cancer referrals have also
dramatically reduced during the pandemic [8], and so there is
a long road to recovery ahead and for none more so than
patients with BC.
Table 1 Changes to treatment due to COVID-19 based on a survey of 156
respondents.
Treatment Status n %
First TURBT (n = 8) Postponed 2 25.0
Cancelled 0 0.0
Going ahead as planned 6 75.0
Subsequent TURBT (n = 16) Postponed 6 37.5
Cancelled 3 18.8
Going ahead as planned 7 43.8
Cystectomy (n = 17) Postponed 9 52.9
Cancelled 3 17.7
Going ahead as planned 5 29.4
Intravesical therapies (BCG and
mitomycin; n = 53)
Postponed 28 52.8
Cancelled 9 17.0
Going ahead as planned 10 18.9
Other/missing 6 11.3
Cystoscopic surveillance (n = 97) Postponed 40 41.2
Cancelled 11 11.3
Going ahead as planned 33 34.0
Other/missing 13 13.4
Neoadjuvant chemotherapy (prior to
cystectomy or radiotherapy; n = 3)
Postponed 0 0.0
Cancelled 0 0.0
Going ahead as planned 2 66.7
Other/missing 1 33.3
Adjuvant chemotherapy (after
cystectomy or radiotherapy; n = 6)
Postponed 3 50.0
Cancelled 1 16.7
Going ahead as planned 2 33.3
Other/missing 0 0.0
Chemotherapy only (n = 2) Postponed 0 0.0
Cancelled 1 50.0
Going ahead as planned 1 50.0
Other/missing 0 0.0
TURBT, transurethral resection of bladder tumour.
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